Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).

Area of Science:

• Pulmonology
• Infectious Diseases
• Clinical Pharmacology

Background:

• Renewed interest exists in using prophylactic antibiotics to decrease exacerbations and enhance quality of life for patients with chronic obstructive pulmonary disease (COPD).
• The efficacy of regular antibiotic treatment in managing COPD exacerbations and improving patient well-being remains a key research question.

Purpose of the Study:

• To evaluate the effectiveness of regular prophylactic antibiotic treatment (continuous, intermittent, or pulsed) in reducing exacerbations and improving quality of life in COPD patients.

Main Methods:

• A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing prophylactic antibiotics with placebo in COPD patients.
• Searched major databases, including the Cochrane Airways Group Trials Register, up to July 2018.
• Included 14 RCTs with 3932 participants, assessing outcomes like exacerbation frequency, quality of life, hospital admissions, lung function, and adverse events.

Main Results:

• Prophylactic antibiotics significantly reduced the proportion of participants experiencing one or more exacerbations (OR 0.57) and the frequency of exacerbations per patient per year (rate ratio 0.67).
• Continuous and intermittent macrolide antibiotic regimens showed greater efficacy than pulsed regimens.
• A statistically significant but clinically minor improvement in quality of life (St George's Respiratory Questionnaire) was observed; no significant effects on hospital admissions, FEV1, serious adverse events, or all-cause mortality were found.

Conclusions:

• Continuous and intermittent prophylactic macrolide antibiotic use (at least three times weekly) offers clinically significant benefits in reducing COPD exacerbations.
• The effectiveness of pulsed antibiotic regimens requires further investigation.
• Concerns regarding antibiotic resistance and adverse effects (e.g., hearing loss, gastrointestinal issues) necessitate a careful balance between individual patient benefits and societal risks of antibiotic overuse.